GCLC and Huntington disease: In a 3-NP-induced mouse model of HD, SFN upregulated NRF2, NQO1, GCL, and HO1, inhibited NFκB, TNF-α, IL-1β and IL-6 in the striatum, and improved motor dysfunction and reduced striatal cell death [155].